Aurinia Pharmaceuticals earnings were $314.1M for the trailing 12 months ending Jun 30, 2026, with 436.4% growth year over year. The latest AUPH earnings report on Jun 30, 2026 announced Q2 2026 earnings of $37.4M, up 8.9% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, AUPH reported annual earnings of $287.2M, with 4,893.1% growth. The next AUPH earnings date is Nov 3, 2026.
AUPH past earnings growth
How has AUPH's earnings growth performed historically?
Aurinia Pharmaceuticals Earnings Reports & History FAQ
What were Aurinia Pharmaceuticals's earnings last quarter?
On AUPH's earnings call on Aug 6, 2026, Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 2026 earnings per share (EPS) of $0.29, up 81.25% year over year. Total AUPH earnings for the quarter were $37.41 million. In the same quarter last year, Aurinia Pharmaceuticals's earnings per share (EPS) was $0.16.
When does Aurinia Pharmaceuticals report earnings?
The next AUPH earnings date is Nov 3, 2026. Add AUPH to your watchlist to be reminded of Aurinia Pharmaceuticals's next earnings date.
Is Aurinia Pharmaceuticals profitable or losing money?
As of the last Aurinia Pharmaceuticals earnings report, Aurinia Pharmaceuticals is currently profitable. Aurinia Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $314.11 million, a 418.03% increase year over year.
What was AUPH's earnings growth in the past year?
As of Aurinia Pharmaceuticals's earnings date in Aug 6, 2026, Aurinia Pharmaceuticals's earnings has grown 436.36% year over year. This is 418.33 percentage points higher than the US Biotechnology industry earnings growth rate of 18.03%. AUPH earnings in the past year totalled $314.11 million.
What are Aurinia Pharmaceuticals's earnings expectations?
The current EPS estimate for Aurinia Pharmaceuticals's earnings report in Nov 3, 2026 is $0.21.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.